Plain-English translation of NCT05225363 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing TAG72-CAR T cells, a new type of treatment made from your own immune cells that have been modified in the laboratory to recognize and attack ovarian cancer. The study will enroll about 33 patients with advanced ovarian cancer that has come back or grown despite platinum chemotherapy. Researchers want to learn if this medication is safe, what dose works best, and whether it can slow or stop the cancer from growing.
Ovarian cancer that no longer responds to standard platinum chemotherapy is very difficult to treat, and patients urgently need new options. This medication represents a different approach — using the body's own immune system to fight the cancer — which may help patients who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
You would first have blood drawn in a process called leukapheresis, where some of your immune cells are collected and sent to the laboratory to be modified. Before receiving the modified cells back, you would receive two chemotherapy drugs ( and ) for 3 days to prepare your body. On day 0, the engineered cells would be infused back into you. You would then have follow-up visits at regular intervals — at 1, 7, 14, 21, and 28 days, then at 2, 3, 6, 9, and 12 months, and then annually for up to 15 years — to monitor your health, check for side effects, and see how well the treatment is working.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States